Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $7.21 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 2.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 36,663 shares of the medical research company’s stock after selling 1,038 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in IQVIA were worth $7,205,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Smith Group Asset Management LLC acquired a new stake in IQVIA in the fourth quarter valued at $1,616,000. Nordea Investment Management AB lifted its stake in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. acquired a new stake in shares of IQVIA during the 4th quarter worth about $941,000. Fifth Third Bancorp lifted its stake in shares of IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after buying an additional 1,521 shares during the last quarter. Finally, Graphene Investments SAS lifted its stake in shares of IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after buying an additional 2,700 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 0.9 %

Shares of IQVIA stock opened at $185.85 on Friday. The firm has a market capitalization of $32.77 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm’s 50 day moving average is $194.94 and its 200 day moving average is $208.73. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $254.80.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IQV has been the subject of a number of research reports. Barclays cut their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Citigroup cut their target price on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Finally, Truist Financial reiterated a “buy” rating and issued a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.